High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study
- 1 March 2000
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 355 (9208) , 999-1003
- https://doi.org/10.1016/s0140-6736(00)90024-2
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast CarcinomaJNCI Journal of the National Cancer Institute, 2000
- Randomised controlled trial of high dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancerEuropean Journal Of Cancer, 1999
- Handling of scientific dishonesty in the Nordic countriesThe Lancet, 1999
- Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvementThe Lancet, 1998
- Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results.Journal of Clinical Oncology, 1997
- High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.Journal of Clinical Oncology, 1997
- High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.Journal of Clinical Oncology, 1995
- A Successful System of Scientific Data Audits for Clinical TrialsJAMA, 1993
- High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.Journal of Clinical Oncology, 1993
- High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.Journal of Clinical Oncology, 1988